Hypercoagulable states

Clinics in Chest Medicine

Volumn 31, Issue 4, 2010, Pages 659-673

  Anderson, Julia A M ^a,b   Weitz, Jeffrey I ^b  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Anticoagulation; Hypercoagulable state; Thrombophilia; Thromboprophylaxis; Thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; ETHINYLESTRADIOL; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; ORAL CONTRACEPTIVE AGENT; PROTHROMBIN; WARFARIN;

ANTIPHOSPHOLIPID SYNDROME; ANTITHROMBIN DEFICIENCY; BLOOD CLOTTING; CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG DOSE TITRATION; DRUG SAFETY; DRUG WITHDRAWAL; ESTROGEN THERAPY; GAIN OF FUNCTION MUTATION; GENE MUTATION; GENETIC ASSOCIATION; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK POPULATION; HUMAN; HYPERCOAGULABILITY; HYPERHOMOCYSTEINEMIA; LABORATORY TEST; LOW DRUG DOSE; MUTATIONAL ANALYSIS; MYELOPROLIFERATIVE DISORDER; OBESITY; PATHOGENESIS; PREGNANCY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION; SOLID TUMOR; THROMBOPHILIA; THROMBOSIS; TREATMENT DURATION; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANTIPHOSPHOLIPID SYNDROME; BLOOD COAGULATION DISORDERS, INHERITED; CONTRACEPTIVE AGENTS, FEMALE; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MASS SCREENING; NEOPLASMS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; SELECTIVE ESTROGEN RECEPTOR MODULATORS; THROMBOCYTOPENIA; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 78049454667     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccm.2010.07.004     Document Type: Review

References (117)

1. Crowther M.A., Kelton J.G. Congenital thrombophilic states associated with venous thrombosis: a qualitative overview and proposed classification system. Ann Intern Med 2003, 138(2):128-134.
2. Jacques P.F., Bostom A.G., Williams R.R., et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996, 93(1):7-9.
3. Salomon O., Steinberg D.M., Zivelin A., et al. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment. Arterioscler Thromb Vasc Biol 1999, 19(3):511-518.
4. Vandenbroucke J.P., Koster T., Briët E., et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994, 3449(8935):1453-1457.
5. Kitchens C.S. Thrombophilia and thrombosis in unusual sites. Hemostasis and thrombosis. Basic principles and clinical practice 1994, 1255-1273. J.B.Lippincott Company, Philadelphia. R.W. Colman, J. Hirsh, V.J. Marder (Eds.).
6. Aiach M., Emmerich J. Thrombophilia genetics. Hemostasis and thrombosis basic principles and clinical practice 2006, 779-793. Lippincott, Williams and Wilkins, Philadelphia. 5th edition. R.W. Colman, V.J. Marder, A.W. Clowes (Eds.).
7. Olson S.T., Björk I. Regulation of thrombin activity by antithrombin and heparin. Semin Thromb Hemost 1994, 20(4):373-409.
8. Perry D., Carrell R. Molecular genetics of human antithrombin deficiency. Hum Mutat 1996, 7(1):7-22.
9. Perry D.J. Antithrombin and its inherited deficiencies. Blood Rev 1994, 8(1):37-55.
10. Ambruso D.R., Leonard B.D., Bies R.D. Antithrombin III deficiency: decreased synthesis of a biochemically normal molecule. Blood 1982, 60(1):78-83.
11. van Boven H., Lane D. Antithrombin and its inherited deficiency states. Semin Hematol 1997, 34(3):188-204.
12. Griffin J.H., Evatt B., Zimmerman T.S. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981, 68(5):1370-1373.
13. Tait R.C., Walker I.D., Reitsma P.H., et al. Prevalence of protein C deficiency in the healthy population. Thromb Haemost 1995, 73(1):87-93.
14. Monagle P., Andrew M., Halton J., et al. Homozygous protein C deficiency: description of a new mutation and successful treatment with low molecular weight heparin. Thromb Haemost 1998, 79(4):756-761.
15. Alhenc-Gelas M., Emmerich J., Gandrille S., et al. Protein C infusion in a patient with inherited protein C deficiency caused by two missense mutations: Arg 178 to Gln and Arg-1 to His. Blood Coagul Fibrinolysis 1995, 6(1):35-41.
16. Pescatore P., Horellou H.M., Conard J., et al. Problems of oral anticoagulation in an adult with homozygous protein C deficiency and late onset of thrombosis. Thromb Haemost 1993, 69(4):311-315.
17. Miletich J.P. Laboratory diagnosis of protein C deficiency. Semin Throm Haemost 1990, 16(2):169-176.
18. Broze G.J., Warren L.A., Novotny W.F., et al. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Blood 1988, 71(2):335-343.
19. Weiss P., Soff G.A., Halkin H., et al. Decline of protein C and S and Factors II, VII, IX and X during the initiation of warfarin therapy. Thromb Res 1987, 45(6):783-790.
20. Manco-Johnson M.J., Marlar R.A., Jacobson L.Y., et al. Severe protein C deficiency in newborn infants. J Pediatr 1988, 113(2):359-363.
21. Wolf M., Boyer-Neumann C., Martinoli J.L., et al. A new functional assay for human protein S activity using activated factor V as substrate. Thromb Haemost 1989, 62(4):1144-1145.
22. Tripodi A. A review of the clinical and diagnostic utility of laboratory tests for the detection of congenital thrombophilia. Semin Thromb Hemost 2005, 31(1):25-32.
23. Vigano-D'Angelo S., d'Angelo A., Kaufman C.E., et al. Protein S deficiency occurs in the nephrotic syndrome. Ann Intern Med 1987, 107(1):42-47.
24. Malm J., Laurell M., Dahlbäck B. Changes in the plasma levels of vitamin K-dependent proteins C and S and of C4b-binding protein during pregnancy and oral contraception. Br J Haematol 1988, 68(4):437-443.
25. Dahlbäck B., Carlsson M., Svensson P.J. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 1993, 90(3):1004-1008.
26. Dahlbäck B. The discovery of activated protein C resistance. J Thromb Haemost 2003, 1(1):3-9.
27. Bertina R.M., Koeleman B.P., Koster T., et al. Mutation in blood coagulation factor V association with resistance to activated protein C. Nature 1994, 369(6475):64-67.
28. Kalafatis M., Bertina R.M., Rand M.D., et al. Characterisation of the molecular defect in factor VR506Q. J Biol Chem 1995, 270(8):4053-4057.
29. Camire R.M., Kalafatis M., Cushman M., et al. The mechanism of inactivation of human platelet factor Va from normal and activated protein C-resistant individuals. J Biol Chem 1995, 270(35):20794-20800.
30. Nicolaes G., Dahlbäck B. Activated protein C resistance (FV Leiden) and thrombosis: factor V mutations causing hypercoagulable states. Hematol Oncol Clin North Am 2003, 17(1):37-61.
31. Chan W.P., Lee C.K., Kwong Y.L., et al. A novel mutation of Arg306 of factor V gene in Hong Kong Chinese. Blood 1998, 91(4):1135-1139.
32. Williamson D., Brown K., Luddington R., et al. Factor V: Cambridge: a new mutation (Arg306-Thr) associated with resistance to activated protein C. Blood 1998, 91(4):1140-1144.
33. Rodegheiro F., Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med 1999, 130(8):643-650.
34. Martinelli I., Mannucci P.M., De Stefano V., et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 1998, 92(7):2353-2358.
35. Bucciarelli P., Rosendaal F.R., Tripodi A., et al. Risks of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance: a multicenter collaborative family study. Arterioscler Thromb Vasc Biol 1999, 19(4):1026-1033.
36. Dahlback B., Hildebrand B. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci U S A 1994, 91(4):1396-1400.
37. Hertzberg M.S. Genetic testing for thrombophilia mutations. Semin Thromb Hemost 2005, 31(1):33-38.
38. Poort S.R., Rosendaal F.R., Reitsma P.H., et al. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996, 88(10):3698-3703.
39. Wolberg A.S., Monroe D.M., Roberts H.R., et al. Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic risk. Blood 2003, 101(8):3008-3013.
40. Kyrle P.A., Mannhalter C., Beguin S., et al. Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene. Arterioscler Thromb Vasc Biol 1998, 18(8):1287-1291.
41. Smirnov M.D., Safa O., Esmon N.L., et al. Inhibition of activated protein C anticoagulant activity by prothrombin. Blood 1999, 94(11):3839-3846.
42. Bauer K. Hypercoagulable states. Hematology, basic principles and practice 2005, 2197-2224. Elsevier Churchill Livingstone, Philadelphia (PA). 4th edition. R. Hoffman, E.J. Benz, S.J. Shattil (Eds.).
43. Zawadzki C., Gaveriaux V., Trillot N., et al. Homozygous G20210A transition in the prothrombin gene associated with severe venous thrombotic disease: two cases in a French family. Thromb Haemost 1998, 80(6):1027-1028.
44. Kosch A., Junker R., Wermes C., et al. Recurrent pulmonary embolism in a 13-year-old homozygous for the prothrombin G20210A mutation combined with protein S deficiency and increased lipoprotein (a). Thromb Res 2002, 105(1):49-53.
45. Kraaijenhagen R.A., in't Anker P.S., Koopman M.M., et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 2000, 83(1):5-9.
46. Meijers J.C., Tekelenburg W.L., Bouma B.N., et al. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 2000, 342(10):696-701.
47. van Hylckama Vlieg A., van der Linden I.K., Bertina R.M., et al. High levels of factor IX increase the risk of venous thrombosis. Blood 2000, 95(12):3678-3682.
48. Lim W., Crowther M.A., Eikelboom J.W. Management of antiphospholipid antibody syndrome. JAMA 2006, 295(9):1050-1057.
49. Rai R.S., Clifford K., Cohe H., et al. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Humanit Rep 1995, 10(12):3301-3304.
50. Brandt J.T., Barna L.K., Triplett D.A. Laboratory identification of lupus anticoagulants: results of the Second International Workshop for Identification of Lupus Anticoagulants. Thromb Haemost 1995, 74(6):1597-1603.
51. Harris E.N., Gharavi A.E., Boey M.L., et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983, 2(8361):1211-1214.
52. Long A., Ginsberg J.S., Brill-Edwards P. The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus: a cross-sectional study. Thromb Haemost 1991, 66(5):520-524.
53. Brey R.L., Chapman J., Levine S.R. Stroke and the antiphospholipid syndrome: consensus meeting Taormina 2002. Lupus 2003, 12(7):508-513.
54. Brey R.L., Escalante A. Neurological manifestations of antiphospholipid antibody syndrome. Lupus 1998, 7(Suppl 2):S67-S74.
55. Carhuapoma J.R., Mitsias P., Levine S.R. Cerebral venous thrombosis and anticardiolipin antibodies. Stroke 1997, 28(12):2363-2369.
56. Warkentin T.E. Heparin-induced thrombocytopenia. Hemostasis and thrombosis basic principles and clinical practice 2006, 1649-1661. Lippincott, Williams and Wilkins, Philadelphia. 5th edition. R.W. Colman, V.J. Marder, A.W. Clowes (Eds.).
57. Warkentin T.E. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003, 121(4):535-555.
58. Warkentin T.E., Kelton J.G. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 2001, 135(7):502-506.
59. Warkentin T.E., Roberts R.S., Hirsh J. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 2003, 163(20):2518-2524.
60. Lee D.H., Warkentin T.E. Frequency of heparin-induced thrombocytopenia. Heparin induced thrombocytopenia 2004, 107-148. Marcel Dekker Inc, New York. 3rd edition. T.E. Warkentin, A. Greinacher (Eds.).
61. Sheridan D., Carter C., Kelton J.G. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986, 67(1):27-30.
62. Greinacher A., Amiral J., Dummel V., et al. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay. Transfusion 1994, 34(5):381-385.
63. Lee A.Y., Levine M.N. Venous thromboembolism and cancer: risks and outcomes. Circulation 2003, 107(23 Suppl 1):I17-121.
64. Lee A.Y. Management of thrombosis in cancer: primary prevention and secondary prophylaxis. Br J Haematol 2006, 128:291-302.
65. Ruf W. Molecular regulation of blood clotting in tumor biology. Haemostasis 2001, 31(Suppl 1):5-7.
66. Gale A.J., Gordon S.G. Update on tumor cell procoagulant factors. Acta Haematol 2001, 106(1-2):25-32.
67. Bertomeu M.C., Gallo S., Lauri D., et al. Chemotherapy enhances endothelial cell reactivity to platelets. Clin Exp Metastasis 1990, 8(6):511-518.
68. Pritchard K.I., Paterson A.H., Paul N.A., et al. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. J Clin Oncol 1996, 14(10):2731-2737.
69. Levine M.N., Lee A.Y., Kakkar A.K. Cancer and thrombosis. Hemostasis and thrombosis. basic principles and clinical practice 2006, 1251-1262. Lippincott, Williams and Wilkins, Philadelphia. 5th edition. R.W. Colman, V.J. Marder, A.W. Clowes (Eds.).
70. Greer I.A. Thrombosis in pregnancy: maternal and fetal issues. Lancet 1999, 353(9160):1258-1265.
71. McColl M.D., Ramsay J.E., Tait R.C., et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 1997, 78(4):1183-1188.
72. Cockett F.B., Thomas M.L. The iliac compression syndrome. Br J Surg 1965, 52(10):816-821.
73. Ginsberg J.S., Brill-Edwards P., Burrows R.F., et al. Venous thrombosis during pregnancy: leg and trimester of presentation. Thromb Haemost 1992, 67(5):519-520.
74. Clark P. Changes of hemostasis variables during pregnancy. Semin Vasc Med 2003, 3(1):13-24.
75. Bremme K. Haemostatic changes in pregnancy. Best Pract Res Clin Haematol 2003, 16(2):153-168.
76. Comp P., Thurnau G.R., Welsh J., et al. Functional and immunologic protein S levels are decreased during pregnancy. Blood 1986, 68(4):881-885.
77. Clark P., Brennand J., Conkie J.A., et al. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb Haemost 1998, 79(6):1166-1170.
78. Stirling Y., Woolf L., North W.R., et al. Haemostasis in normal pregnancy. Thromb Haemost 1984, 52:176-182.
79. Eichinger S., Weltermann A., Philipp K., et al. Prospective evaluation of hemostatic system activation and thrombin potential in healthy pregnant women with and without factor V Leiden. Thromb Haemost 1999, 82(4):1232-1236.
80. Martinelli I., Legnani C., Bucciarelli P. Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia. Thromb Haemost 2001, 86(3):800-803.
81. Greer I.A. Inherited thrombophilia and venous thromboembolism. Best Pract Res Clin Obstet Gynaecol 2003, 17(3):413-425.
82. Gerhardt A., Scharf R., Beckmann M., et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 2000, 342(6):374-380.
83. Friederich P.W., Sanson B.J., Simioni P., et al. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med 1996, 125(12):955-960.
84. Bates S.M., Greer I.A., Hirsh J., et al. Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on antithrombotic and thrombolytic therapy. Chest 2006, 126(Suppl 3):627S.
85. Vandenbroucke J.P., Rosing J., Bloemenkamp K.W., et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001, 344(20):1527-1535.
86. Daly E., Vessey M.P., Hawkins M.M., et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996, 348(9033):977-980.
87. Martinelli I. Risk factors in venous thromboembolism. Thromb Haemost 2001, 86(1):395-403.
88. Rosendaal F.R. Oral contraceptives and screening for factor V Leiden. Thromb Haemost 1996, 75(3):524-525.
89. Prandoni P., Lensing A.W., Cogo A., et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996, 125(1):1-7.
90. Heit J.A., Silverstein M.D., Mohr D.N., et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000, 160(6):809-815.
91. Kearon C., Gent M., Hirsh J., et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999, 340(12):901-907.
92. Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb Haemost 1999, 81(2):165-176.
93. Ray J. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med 1998, 158(19):2101-2106.
94. Finkelstein J.D. Methionine metabolism in mammals. J Nutr Biochem 1990, 1(5):228-237.
95. Kluijtmans L.A., van den Huevel L.P., Boers G.H., et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996, 58(1):35-41.
96. Jacques P.F., Selhub J., Bostom A.G., et al. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 1999, 340(19):1449-1454.
97. Molloy A.M., Scott J.M. Folates and prevention of disease. Public Health Nutr 2001, 4(2B):601-609.
98. Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. BMJ 1998, 316:894-898.
99. Lonn E., Yusuf S., Arnold M.J., et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006, 354(15):1567-1577.
100. Dreyfus M., Magny J.F., Bridey F., et al. Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate. N Engl J Med 1991, 325(22):1565-1568.
101. Monagle P., Chan A., Massicotte P., et al. Antithrombotic therapy in children: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004, 126(3):645-687.
102. Lechner K., Kyrle P. Antithrombin III concentrates-are they clinically useful?. Thromb Haemost 1995, 73(3):340-348.
103. Crowther M.A., Ginsberg J.S., Julian J., et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003, 349(7):631-639.
104. Finazzi G., Marchioli R., Brancaccio V. A randomised clinical trial of high-intensity warfarin versus conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. J Thromb Haemost 2005, 3(5):848-853.
105. Lee A.Y.Y., Levine M.N., Baker R.I., et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003, 349(2):146-153.
106. Marchetti M., Pistorio A., Barone M., et al. Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: a cost-effectiveness analysis. Am J Med 2001, 111(2):130-139.
107. Levine M.N., Hirsh J., Gent M., et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep venous thrombosis. Thromb Haemost 1995, 74(2):606-611.
108. Agnelli G., Prandoni P., Santamaria M.G., et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep vein thrombosis. N Engl J Med 2001, 345(3):165-169.
109. Buller H.R., Agnelli G., Hull R.D., et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004, 126(3):401S-428S.
110. Ridker P.M., Goldhaber S.Z., Danielson E., et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003, 348(15):1425-1434.
111. Gallus A.S. Management options for thrombophilias. Semin Thromb Hemost 2005, 31(1):118-126.
112. Mazzolai L., Hohlfeld P., Spertini F., et al. Fondaparinux is a safe alternative in case of heparin intolerance during pregnancy. Blood 2006, 108(5):1569-1570.
113. McKenna R., Cole E.R., Vasan U. Is warfarin sodium contraindicated in lactating mothers?. J Pediatr 1983, 103(2):325-327.
114. Brill-Edwards P., Ginsberg J.A., Gent M., et al. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. N Engl J Med 2000, 343(20):1439-1444.
115. Greaves M., Baglin T. Laboratory testing for heritable thrombophilia; impact on clinical management of thrombotic disease. Br J Haematol 2000, 109(4):699-703.
116. Mannucci P.M. Genetic hypercoagulability: prevention suggests testing family members. Blood 2001, 98(1):21-22.
117. Heron E., Lozinguez O., Alhenc-Gelas M., et al. Hypercoagulable states in primary upper-extremity deep vein thrombosis. Arch Intern Med 2000, 160(3):382-386.